Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
Details : The launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, which is the generic equivalent of ALIMTA® (pemetrexed for injection) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).
Product Name : Pemetrexed-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EVER Pharma gains EU marketing authorization for value-added Pemetrexed
Details :
Product Name : Pemetrexed EVER Pharma
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Gains EU CHMP Opinion for KEYTRUDA® in Unresectable Malignant Pleural Mesothelioma
Details : FDA has already approved Keytruda (Pembrolizumab) in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic MPM.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Pembrolizumab,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves KEYTRUDA® Plus Chemo for Advanced Malignant Pleural Mesothelioma
Details : FDA has approved Keytruda (Pembrolizumab) in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic MPM.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Pembrolizumab,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Shilpa Medicare
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Launches Pemetrexed Injection
Details : Pemrydi (pemetrexed) is the first ready-to-use formulation approved for commercialization in the US market. It is indicated for patients suffering from non-small cell lung cancer.
Product Name : Pemrydi RTU
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Shilpa Medicare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pemetrexed,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches PEMRYDI RTU®, Ready-to-Use Oncology Injectable
Details : Pemrydi RTU, a folate analog inhibitor, is the first ready-to-use pemetrexed for injection, approved with pembrolizumab and platinum chemo for metastatic non-squamous NSCLC.
Product Name : Pemrydi RTU
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : Pemetrexed,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pemetrexed,Cisplatin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
Details : Pemrydi RTU (pemetrexed) is indicated, in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberration..
Product Name : Pemrydi RTU
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Pemetrexed,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pemetrexed,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PEMFEXY® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations.
Product Name : Pemfexy
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Pemetrexed,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Durvalumab,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Exploratory analysis from POSEIDON Phase III trial also showed trends for overall survival benefit with a limited course of tremelimumab added to Imfinzi (durvalumab) and chemotherapy in subgroups with high unmet need.
Product Name : Imfinzi
Product Type : Antibody
Upfront Cash : Inapplicable
November 09, 2022
Lead Product(s) : Durvalumab,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission
Details : Tyvyt (sintilimab),is a novel PD-1 inhibitor, is under review for the first-line treatment of people with non-squamous non-small cell lung cancer based on the ORIENT-11 trial conducted exclusively in China.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Sintilimab,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable